17 assets in Cervical Squamous Cell Carcinoma

Therapeutic assets addressing Cervical Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cetuximab Cervical Squamous Cell Carcinoma	Hummingbird Bioscience	P1/2	CCC (55)
Atezolizumab Cervical Squamous Cell Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Cyclophosphamide Cervical Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (48)
Fludarabine Cervical Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (48)
Idp-001 Cervical Squamous Cell Carcinoma	InduPro, Inc.	P1/2	CCC (48)
scg142 Cervical Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (48)
Ale.P02 Cervical Squamous Cell Carcinoma	Alentis Therapeutics AG	P1/2	CC (47)
Ale.P03 Cervical Squamous Cell Carcinoma	Alentis Therapeutics AG	P1/2	CC (47)
Docetaxel Cervical Squamous Cell Carcinoma	Hummingbird Bioscience	P1/2	CC (47)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-3101 (89.9%) -(Ighd) -Ighj401 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg101 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-1201 (85.3%)-Igkj201 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa Cervical Squamous Cell Carcinoma	Hummingbird Bioscience	P1/2	CC (47)
Bbi-355 Cervical Squamous Cell Carcinoma	Boundless Bio, Inc.	P1	CC (43)
Bbi-825 Cervical Squamous Cell Carcinoma	Boundless Bio, Inc.	P1	CC (43)
Durvalumab Cervical Squamous Cell Carcinoma	NeoTX Therapeutics Ltd.	P1	CC (43)
Evolve104 Cervical Squamous Cell Carcinoma	EvolveImmune United, Inc	P1	CC (43)
Futibatinib Cervical Squamous Cell Carcinoma	Boundless Bio, Inc.	P1	CC (43)
Naptumomab Estafenatox Cervical Squamous Cell Carcinoma	NeoTX Therapeutics Ltd.	P1	CC (43)
Obinutuzumab Cervical Squamous Cell Carcinoma	NeoTX Therapeutics Ltd.	P1	CC (43)